Diagonal Therapeutics is developing a new class of clustering antibody medicines designed to address the root causes of severe genetic diseases. Using our DIAGONAL platform, we engineer clustering bispecific antibodies to restore healthy cell signaling in genetically driven diseases. This innovative approach offers potential therapies that can modify disease biology, providing lasting benefits for patients with limited treatment options.
Our lead program, DIAG723, targets hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH), two serious vascular diseases with significant unmet needs. It focuses on the dysregulated signaling that contributes to both conditions, showing promising results in early models.
With strong investor support and a growing clinical pipeline, Diagonal Therapeutics is redefining treatment possibilities for challenging genetic diseases, moving beyond symptom relief to disease modification.
Learn more at: www.diagonaltx.com
Company Details
- Employees
- 27
- Founded
- -
- Address
- Watertown, Massachusetts 02472, Us
- Industry
- Biotechnology
- Website
- http://www.diagonaltx.com
- HQ
- Watertown, Massachusetts
Diagonal Therapeutics Questions
Diagonal Therapeutics's website is http://www.diagonaltx.com
Diagonal Therapeutics's LinkedIn profile is https://www.linkedin.com/company/diagonal-therapeutics
Diagonal Therapeutics has
27 employees.
View email and phone details for 27
employees at Diagonal Therapeutics.
Diagonal Therapeutics's industry is
Biotechnology
Diagonal Therapeutics's top competitors are
Delphia Therapeutics,
Selux Diagnostics, Inc,
Beam Therapeutics,
Alterome Therapeutics, Inc,
Clasp Therapeutics,
Nvelop Therapeutics,
Obsidian Therapeutics,
Artbio,
Contineum Therapeutics,
Seaport Therapeutics.
Diagonal Therapeutics's categories are Biotechnology
Diagonal Therapeutics's founding year is 2022
